FDA Approves Supplemental New Drug Application for Veltassa® Removing Boxed Warning Regarding Drug-Drug Interactions
The updated US label for Veltassa® recommends patients take Veltassa® at least 3 hours before or 3 hours after other ora…
The updated US label for Veltassa® recommends patients take Veltassa® at least 3 hours before or 3 hours after other ora…
Velphoro® (sucroferric oxyhydroxide) has received EU marketing authorisation from the European Commission for the contro…
. - Velphoro® (PA21) recommended for approval in the European Union for the treatment of hyperphosphatemia in adult Chr…
Velphoro® (sucroferric oxyhydroxide) has received US Food and Drug Administration (FDA) approval for the control of seru…